UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 51

Sortiert nach

Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans

Kidney international, 2011-03, Vol.79 (S120), p.S20-S27

2011

Link zum Volltext

Verfügbarkeit prüfen

Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats

Diabetes (New York, N.Y.), 2008-06, Vol.57 (6), p.1723-1729

2008

Link zum Volltext

Verfügbarkeit prüfen

Carcinogenicity Risk Assessment Supports the Chronic Safety of Dapagliflozin, an Inhibitor of Sodium–Glucose Co-Transporter 2, in the Treatment of Type 2 Diabetes Mellitus

Diabetes therapy, 2014-06, Vol.5 (1), p.73-96

2014

Link zum Volltext

Verfügbarkeit prüfen

Unique pharmacology of a novel allosteric agonist/sensitizer insulin receptor monoclonal antibody

Molecular metabolism (Germany), 2018-04, Vol.10, p.87-99

2018

Link zum Volltext

Verfügbarkeit prüfen

SGLT2 Deletion Improves Glucose Homeostasis and Preserves Pancreatic β-Cell Function

Diabetes (New York, N.Y.), 2011-03, Vol.60 (3), p.890-898

2011

Link zum Volltext

Verfügbarkeit prüfen

Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members

Diabetes therapy, 2010-12, Vol.1 (2), p.57-92

2010

Link zum Volltext

Verfügbarkeit prüfen

Discovery of novel pyridinones as MGAT2 inhibitors for the treatment of metabolic disorders

Bioorganic & medicinal chemistry letters, 2023-07, Vol.91, p.129362-129362, Article 129362

2023

Link zum Volltext

Verfügbarkeit prüfen

Optimization of physicochemical properties of pyrrolidine GPR40 AgoPAMs results in a differentiated profile with improved pharmacokinetics and reduced off-target activities

Bioorganic & medicinal chemistry, 2023-05, Vol.85, p.117273-117273, Article 117273

2023

Link zum Volltext

Verfügbarkeit prüfen

Screening Hit to Clinical Candidate: Discovery of BMS-963272, a Potent, Selective MGAT2 Inhibitor for the Treatment of Metabolic Disorders

Journal of medicinal chemistry, 2021-10, Vol.64 (19), p.14773-14792

2021

Link zum Volltext

Verfügbarkeit prüfen

Novel Monoclonal Antibody Is an Allosteric Insulin Receptor Antagonist That Induces Insulin Resistance

Diabetes (New York, N.Y.), 2017-01, Vol.66 (1), p.206-217

2017

Link zum Volltext

Verfügbarkeit prüfen

SGLT2 knockout prevents hyperglycemia and is associated with reduced pancreatic β-cell death in genetically obese mice

Islets, 2018-09, Vol.10 (5), p.181-189

2018

Link zum Volltext

Verfügbarkeit prüfen

Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus

Diabetes, metabolic syndrome and obesity, 2012-01, Vol.5 (default), p.135-148

2012

Link zum Volltext

Verfügbarkeit prüfen

Eleven Amino Acid Glucagon-like Peptide-1 Receptor Agonists with Antidiabetic Activity

Journal of medicinal chemistry, 2009-12, Vol.52 (23), p.7788-7799

2009

Link zum Volltext

Verfügbarkeit prüfen

Comparative Study of p53 Gene and Protein Alterations in Human Astrocytic Tumors

Journal of neuropathology and experimental neurology, 1993-01, Vol.52 (1), p.31-38

1993

Link zum Volltext

Verfügbarkeit prüfen

Nonclinical Toxicology Assessments Support the Chronic Safety of Dapagliflozin, a First-in-Class Sodium-Glucose Cotransporter 2 Inhibitor

International journal of toxicology, 2013-09, Vol.32 (5), p.336-350

2013

Link zum Volltext

Verfügbarkeit prüfen

Aglycone exploration of C-arylglucoside inhibitors of renal sodium-dependent glucose transporter SGLT2

Bioorganic & medicinal chemistry letters, 2008-09, Vol.18 (17), p.4770-4773

2008

Link zum Volltext

Verfügbarkeit prüfen

Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity

Oncogene, 1999-02, Vol.18 (8), p.1529-1535

1999

Link zum Volltext

Verfügbarkeit prüfen

Targeting Renal Glucose Reabsorption for the Treatment of Type 2 Diabetes Mellitus Using the SGLT2 Inhibitor Dapagliflozin

Postgraduate medicine, 2012-07, Vol.124 (4), p.62-73

2012

Link zum Volltext

Verfügbarkeit prüfen

Cloning and characterization of a mouse gene with homology to the human von Hippel-Lindau disease tumor suppressor gene : implications for the potential organization of the human von Hippel-Lindau disease gene

Cancer research (Chicago, Ill.), 1995-02, Vol.55 (4), p.743-747

1995

Link zum Volltext

Verfügbarkeit prüfen

The von Hippel-Lindau Tumor Suppressor Protein Is Required for Proper Assembly of an Extracellular Fibronectin Matrix

Molecular cell, 1998-06, Vol.1 (7), p.959-968

1998

Link zum Volltext

Verfügbarkeit prüfen

SGLT2 deletion improves glucose homeostasis and preserves pancreatic [beta]-cell function

Diabetes (New York, N.Y.), 2011-03, Vol.60 (3), p.890

2011

Link zum Volltext

Verfügbarkeit prüfen

SGLT2 deletion improves glucose homeostasis and preserves pancreatic [beta]-cell function

Diabetes (New York, N.Y.), 2011-03, Vol.60 (3), p.890

2011

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 51

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(45)
Mit Volltextzugriff
(49)

Publikationsform

Artikel
(51)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans

Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats

Carcinogenicity Risk Assessment Supports the Chronic Safety of Dapagliflozin, an Inhibitor of Sodium–Glucose Co-Transporter 2, in the Treatment of Type 2 Diabetes Mellitus

Unique pharmacology of a novel allosteric agonist/sensitizer insulin receptor monoclonal antibody

SGLT2 Deletion Improves Glucose Homeostasis and Preserves Pancreatic β-Cell Function

Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members

Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes

Discovery of novel pyridinones as MGAT2 inhibitors for the treatment of metabolic disorders

Optimization of physicochemical properties of pyrrolidine GPR40 AgoPAMs results in a differentiated profile with improved pharmacokinetics and reduced off-target activities

Screening Hit to Clinical Candidate: Discovery of BMS-963272, a Potent, Selective MGAT2 Inhibitor for the Treatment of Metabolic Disorders

Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists

Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode

Novel Monoclonal Antibody Is an Allosteric Insulin Receptor Antagonist That Induces Insulin Resistance

SGLT2 knockout prevents hyperglycemia and is associated with reduced pancreatic β-cell death in genetically obese mice

Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus

Eleven Amino Acid Glucagon-like Peptide-1 Receptor Agonists with Antidiabetic Activity

Comparative Study of p53 Gene and Protein Alterations in Human Astrocytic Tumors

Nonclinical Toxicology Assessments Support the Chronic Safety of Dapagliflozin, a First-in-Class Sodium-Glucose Cotransporter 2 Inhibitor

Aglycone exploration of C-arylglucoside inhibitors of renal sodium-dependent glucose transporter SGLT2

Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity

Targeting Renal Glucose Reabsorption for the Treatment of Type 2 Diabetes Mellitus Using the SGLT2 Inhibitor Dapagliflozin

Cloning and characterization of a mouse gene with homology to the human von Hippel-Lindau disease tumor suppressor gene : implications for the potential organization of the human von Hippel-Lindau disease gene

The von Hippel-Lindau Tumor Suppressor Protein Is Required for Proper Assembly of an Extracellular Fibronectin Matrix

SGLT2 deletion improves glucose homeostasis and preserves pancreatic [beta]-cell function

SGLT2 deletion improves glucose homeostasis and preserves pancreatic [beta]-cell function

Suchergebnisse filtern